Catalent (CTLT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Catalent, Inc. Reports Second Quarter 2016 Results
February 9, 2016 4:16 PM ESTRevenue in line with prior year as reported and increased 6% in constant currency to $454.9 million from second quarter 2015 Adjusted Net Income totaled $44.9 million, or $0.36 per diluted share Entered into a research collaboration with Roche to develop next generation molecules using Catalents proprietary SMARTag technology Announced a long-term exclusive agreement with Pfizer to produce Nexium® 24HR, its leading OTC heartburn medication
SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE:... More
